Patent assignee · US · COMPANY

IMMUNOGEN, INC.

🏢 View company profile →
257Patents
201Active
257Granted
56Portfolio score

Filing activity: Jul 13, 1992 → Jun 15, 2022 · 43 expiring within 5 years

Most-cited patents

PatentTitleAreaCited byStatus
US5208020A Cytotoxic agents comprising maytansinoids and their therapeutic use Emerging Cross-Sectional Technologies 747 Expired
US5416064A Cytotoxic agents comprising maytansinoids and their therapeutic use Emerging Cross-Sectional Technologies 487 Expired
US5639641A Resurfacing of rodent antibodies Chemistry; Metallurgy 345 Expired
US6441163B1 Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents Human Necessities 272 Expired
US5475092A Cell binding agent conjugates of analogues and derivatives of CC-1065 Human Necessities 269 Expired
US5585499A Cyclopropylbenzindole-containing cytotoxic drugs Human Necessities 236 Expired
US5846545A Targeted delivery of cyclopropylbenzindole-containing cytotoxic drugs Human Necessities 230 Expired
US7276497B2 Cytotoxic agents comprising new maytansinoids Human Necessities 211 Expired
US6716821B2 Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same Human Necessities 200 Expired
US6630579B2 Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use Human Necessities 190 Expired
US6333410A Process for the preparation and purification of thiol-containing maytansinoids Human Necessities 170 Expired
US7097840B2 Methods of treatment using anti-ErbB antibody-maytansinoid conjugates Chemistry; Metallurgy 149 Expired
US7303749B1 Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents Chemistry; Metallurgy 139 Expired
US7368565B2 Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents Human Necessities 133 Expired
US7601354B2 Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents Emerging Cross-Sectional Technologies 127 Active
US8088387B2 Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates Emerging Cross-Sectional Technologies 122 Active
US6340701B1 Cytotoxic agents comprising taxanes and their therapeutic use Emerging Cross-Sectional Technologies 109 Expired
US6596757B1 Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use Human Necessities 91 Expired
US6913748B2 Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs Human Necessities 77 Expired
US6436931B1 Cytotoxic agents comprising taxanes and their therapeutic use Emerging Cross-Sectional Technologies 73 Expired
US6534660B1 CC-1065 analog synthesis Emerging Cross-Sectional Technologies 71 Expired
US6372738B1 Cytotoxic agents comprising taxanes and their therapeutic use Emerging Cross-Sectional Technologies 67 Expired
US8337856B2 Methods of treatment using anti-ERBB antibody-maytansinoid conjugates Chemistry; Metallurgy 65 Active
US6756397B2 Prodrugs of CC-1065 analogs Emerging Cross-Sectional Technologies 58 Expired
US8426402B2 Benzodiazepine derivatives Chemistry; Metallurgy 56 Active

Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.